Philosophy, in particular, helps students grapple with complexity, see from multiple perspectives, and cultivate intellectual ...

South Korean President Lee Jae-myung recently quipped in Washington that he looked forward to Donald Trump’s next meeting ...

We’re seeking volunteers for our next 11-week, Opening Minds Through Arts (OMA) series. Once per week volunteers will be paired with older adults living with dementia to create abstract art projects ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability ...

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industryBased on a novel ...

The $90 million project on the Ben Franklin Parkway breaks conventions by letting Alexander 'Sandy' Calder's work speak for ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE ...

Sedgeley speaks in an upbeat tone when reflecting on everything from the state of wolf reintroduction in Colorado to his side ...

Supriya Chakrabarti, Distinguished University Professor, Department of Physics and Applied Physics, University of Massachusetts Lowell and Director, Lowell Center for Space Science and Technology will ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.